NPHCOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
NUTRA PHARMA CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $806.69K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
$0.0000 (0.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
NUTRA PHARMA CORP saw revenue fall 49.0% to $160.82K over the twelve months to Jun 30, 2026. Free cash flow was -$1.19M.
Revenue
$160.82K
-49.0% vs. a year earlier
Operating income
-$1.64M
TTM Q2 2026
Free cash flow
-$1.19M
FY2025
EPS, diluted
$0.00
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $806.69K
- P/E ratio
- –
- Price to sales
- 5.02
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -147.52%
Fundamentals
- Revenue
- $160.82K
- Net income
- -$5.42M
- EPS, diluted
- $0.00
- Free cash flow
- -$1.19M
- Book value per share
- -$0.00
- Diluted shares
- 8.07B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$160.82K-49.0% YoY
Gross profit
$104.27K-62.7% YoY
Operating income
-$1.64M
Net income
-$5.42M
EPS, diluted
$0.00
Free cash flow
–
Reported periodTrailing twelve months